BRIEF-Tetraphase Pharmaceuticals Announces Everest

BRIEF-Tetraphase Pharmaceuticals Announces Everest Medicines’ Submission Of Drug Application For Eravacycline In Complicated Intra-Abdominal Infection To The China FDA

June 4 (Reuters) - Tetraphase Pharmaceuticals Inc:

* TETRAPHASE PHARMACEUTICALS ANNOUNCES EVEREST MEDICINES’ SUBMISSION OF AN INVESTIGATIONAL NEW DRUG APPLICATION FOR ERAVACYCLINE IN COMPLICATED INTRA-ABDOMINAL INFECTION TO THE CHINA FOOD AND DRUG ADMINISTRATION

* TETRAPHASE PHARMACEUTICALS - AS A RESULT OF IND SUBMISSION, TETRAPHASE WILL RECEIVE A MILESTONE PAYMENT OF $2.5 MILLION

* TETRAPHASE - PER TERMS OF DEAL, CO MAY RECEIVE FUTURE CLINICAL, REGULATORY MILESTONES OF UP TO $14 MILLION AS WELL AS SALES MILESTONES OF UP TO $20 MILLION

* TETRAPHASE-IS ELIGIBLE TO RECEIVE DOUBLE-DIGIT TIERED ROYALTIES ON NET SALES OF ERAVACYCLINE IN CHINA, TAIWAN,HONG KONG, MACAU, SOUTH KOREA, SINGAPORE